Therefore, in contrast to the use of CXCR4 antagonists that mobilize AML cells from the BM to start dividing to be subsequently treated with chemotherapy, our approach is capable of directly killing quiescent AML in the BM niche. This evidence concerns the gene CXCR4 and acute myeloid leukemia.